Declared bankruptcy in May 2023
LHDX - Lucira Health, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
EmeryVille,
United States
Type: Equity
LHDX price evolution
LHDX
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.77 | $74.96 | $120.55 | $105.98 |
| Short term investments | ||||
| Net receivables | $19.22 | $15.97 | $51.64 | $35.43 |
| Inventory | $55.63 | $119.58 | $72.91 | $50.78 |
| Total current assets | $120.47 | $220.53 | $260.09 | $206.28 |
| Long term investments | ||||
| Property, plant & equipment | $66 | $65.51 | $42.01 | $33.69 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $189.19 | $289.04 | $304.36 | $240.35 |
| Current liabilities | ||||
| Accounts payable | $25.17 | $24.58 | $23.14 | $19.37 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $82.52 | $57.93 | $70 | $50.33 |
| Long term debt | $29.41 | $29.21 | $29.02 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $128.3 | $103.97 | $99.73 | $51.55 |
| Shareholders' equity | ||||
| Retained earnings | -$264 | -$137.14 | -$115.46 | -$128.54 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $105.98 | $60.55 | $4.1 | $0.1 |
| Short term investments | ||||
| Net receivables | $35.43 | $0.29 | $1.79 | $2.48 |
| Inventory | $50.78 | $4.87 | ||
| Total current assets | $206.28 | $70.23 | $6.13 | $2.69 |
| Long term investments | ||||
| Property, plant & equipment | $33.69 | $19.41 | $0.37 | $1.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22.47 | $1.47 | ||
| Total investments | ||||
| Total assets | $240.35 | $92.7 | $7.61 | $4.27 |
| Current liabilities | ||||
| Accounts payable | $19.37 | $3.98 | $0.57 | $0.93 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $50.33 | $8.86 | $1.6 | $5.49 |
| Long term debt | $24.69 | |||
| Total noncurrent liabilities | $146.15 | $31.67 | ||
| Total debt | ||||
| Total liabilities | $51.55 | $155.01 | $33.27 | $6.82 |
| Shareholders' equity | ||||
| Retained earnings | -$128.54 | -$63.71 | -$26.37 | -$17.9 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.27 | |||
| Cost of revenue | ||||
| Gross Profit | -$1.67 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $31.19 | $13.86 | $9.82 | |
| Operating income | -$31.93 | -$13.86 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.05 | $0.09 | -$0.37 | |
| Net income | ||||
| Net income | -$37.35 | -$8.47 | -$6.54 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 | 30 Oct 2021 |
|---|---|---|---|---|
| Net income | -$57.01 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$90.84 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$14.23 | -$8.13 | -$15.39 | -$10.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $29.22 | $29.2 | $161.7 | $160.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$29.08 | $15.77 | $45.43 | $59.07 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$37.35 | -$8.47 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$32.52 | -$7.06 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$15.39 | -$18.81 | -$0.07 | -$0.15 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $161.7 | $107.79 | $11.14 | $3.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $45.43 | $56.45 | $4 | -$2.84 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 40.45M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.98 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.46 |
| Quick ratio | 0.79 |